Serina Therapeutics, Inc.
Serina Therapeutics, Inc. (NASDAQ: SRNA) is a clinical-stage biotechnology company developing a pipeline of drug product candidates designed to treat neurological diseases and other indications. The company's proprietary POZ drug delivery technology, based on poly(2-oxazoline), is engineered to enable modification of… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Serina Therapeutics, Inc. does
In the company’s own words
Serina Therapeutics, Inc. (NASDAQ: SRNA) is a clinical-stage biotechnology company developing a pipeline of drug product candidates designed to treat neurological diseases and other indications. The company's proprietary POZ drug delivery technology, based on poly(2-oxazoline), is engineered to enable modification of existing drugs and novel drug candidates to improve efficacy and safety profiles across multiple therapeutic modalities including small molecules, RNA-based therapeutics, and antibody-based drug conjugates.
The company's core technology addresses limitations of existing polymer delivery systems like polyethylene glycol by offering advantages in synthesis stability, reduced immunogenicity, higher drug loading capacity, lack of tissue accumulation, and targeting capabilities. POZ polymers are synthesized from inexpensive, stable starting materials and can be stored at room temperature, contrasting with PEG's manufacturing complexity and storage requirements. The company's lead product candidate, SER 252, is a POZ conjugate of apomorphine being developed for advanced Parkinson's disease, designed to provide continuous dopaminergic stimulation via subcutaneous injection one to two times weekly without the skin reactions associated with existing infusion therapies.
Serina's development pipeline also includes SER 214, a POZ-rotigotine conjugate that completed Phase Ia clinical trials and served as proof-of-principle for the POZ platform technology. The company is advancing preclinical research on POZ-lipids as a non-immunogenic alternative to PEG-lipids in lipid nanoparticles for RNA-based therapeutics targeting infectious diseases, cancer immunology, and gene therapy applications.
In October 2023, the company entered into a non-exclusive license agreement with Pfizer for POZ polymer technology in lipid nanoparticle drug delivery formulations, receiving a three million dollar upfront payment with additional milestone and royalty payments contingent on development and commercialization success. The company received FDA clearance of its IND application for SER 252 in January 2026 and enrolled its first patient in Phase 1b clinical trials in February 2026. Serina maintains an extensive patent portfolio covering POZ technology and product candidates, with applications filed internationally to protect its intellectual property and competitive position in the polymer therapeutics field.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- HUNTSVILLE, AL
- Fiscal year end
- December
- CIK
- 1708599
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Serina Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Serina Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Serina Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Serina Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Serina Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”